

CONFERENCE AGENDA



H. Lee Moffitt Cancer Center
& Research Institute
An NCI Comprehensive Cancer Center

Presents

*Molecular Targets in Cancer Therapy:
Fourth Biennial Meeting*

*Mechanism
and
Therapeutic Reversal
of Immune
Suppression in Cancer*

January 25 – 28, 2007



*Sheraton Sand Key Resort
Clearwater Beach, Florida*

Jointly Sponsored by:



Conference Agenda

4th Biennial Molecular Targets in Cancer Therapy: Mechanism & Therapeutic Reversal of Immune Suppression in Cancer

January 25-28, 2007

Sheraton Sand Key Resort, Clearwater Beach, Florida

Thursday, January 25, 2007	
Registration begins at 3 p.m.	Lobby 3
6 p.m. – 7:45 p.m.	
Welcome Dinner and Opening Remarks	Palm/Bay
<i>D. Gabrilovich, MD, PhD, Organizing Committee Chair, H. Lee Moffitt Cancer Center & Research Institute, Tampa</i> <i>W. Dalton, PhD, MD, Director and CEO, H. Lee Moffitt Cancer Center & Research Institute, Tampa</i> <i>W. J. Pledger, PhD, Deputy Center Director, H. Lee Moffitt Cancer Center & Research Institute</i> <i>M. Foti, Chief Operating Officer, American Association for Cancer Research, Philadelphia</i>	
7:45 – 8:30 p.m.	
Keynote Lecture	Palm/Bay
Chairperson: W. Dalton, PhD, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa	
Checkpoint Blockade in Cancer Immunotherapy <i>James P. Allison, PhD, Memorial Sloan Kettering Cancer Center, New York</i>	
8:30 – 9:30 p.m.	
Session 1: Cancer Immunotherapy – Successes and Challenges	Palm/Bay
Chairperson: W. Dalton, PhD, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa	
A Dendritic Cell Vaccine with p53 as the Tumor Antigen for Small Cell Lung Cancer <i>Scott Antonia, MD, PhD, H. Lee Moffitt Cancer Center & Research Institute, Tampa</i>	
Tipping the Immune System Balance in Favor of Effective Anti-Cancer Therapy <i>Elizabeth Jaffee, MD, Johns Hopkins University, Baltimore</i>	

Friday, January 26, 2007

Registration begins at 7 a.m.	Lobby 3
7:00 – 8:00 a.m.	
Breakfast	Palm/Bay
8:00 – 10:00 a.m.	
Session 2: Antigen Presenting Cells & Immune Suppression: Mechanisms of T-Cell Non-Responsiveness	Island Ballroom
Chairperson: J. Mulé, PhD, H. Lee Moffitt Cancer Center & Research Institute, Tampa	
Regulatory T-Cells and Cancer <i>Hy Levitsky, MD, Johns Hopkins University, Baltimore</i>	
Programming of CD+8 T-Cell Tolerance <i>Stephen Schoenberger, PhD, La Jolla Institute for Allergy & Immunology, San Diego</i>	
The B7 Family Molecules in Cancer Evasion <i>Lieping Chen, MD, PhD, Johns Hopkins University, Baltimore</i>	
T Regulatory Cells and AICD: Two Intrinsic Mechanisms for Immune Suppression <i>Bijay Mukherji, MD, University of Connecticut Health Center, Farmington</i>	
10:00 – 10:30 a.m.	
Break	Palm/Bay
10:30 – 12:30 p.m.	
Session 3: Dual Roles of Dendritic Cells and Cancer	Island Ballroom
Chairperson: S. Antonia, MD, PhD, H. Lee Moffitt Cancer Center & Research Institute, Tampa	
T-Cell Regulation by Dendritic Cells Expressing Indoleamine 2,3 Dioxygenase (IDO) <i>Andrew Mellor, PhD, Medical College of Georgia, Augusta</i>	
Molecular Mechanisms of Negative Signaling by Cancer Associated HPV in Immune Escape <i>W. Martin Kast, PhD, University of South California, Los Angeles</i>	
Antigen Presenting Cells in Human Tumor Microenvironment <i>Weiping Zou, MD, PhD, Tulane University, New Orleans</i>	
Mechanisms of Dendritic Cell Dysfunction in Cancer <i>Michael Shurin, MD, PhD, University of Pittsburgh, Pittsburgh</i>	
12:30 – 1:30 p.m.	
Lunch	Rusty's Dining Room

1:40 – 4:00 p.m.	
Session 4: Cellular and Molecular Mechanisms of Immune Suppression in Cancer	Island Ballroom
Chairperson: J. Djeu, PhD, H. Lee Moffitt Cancer Center & Research Institute, Tampa	
<p>Regulation and Therapeutic Inhibition of IDO in Cancer <i>George C. Prendergast, PhD, Lankenau Institute for Medical Research, Wynnewood</i></p> <p>Dual Roles of CD40 in the Development of Tumor-Specific T-Regulatory Cells and its Potential Use in Immune Therapy for Cancer <i>Shu-Hsia Chen, PhD and Ping-Ying Pan, PhD, Mount Sinai School of Medicine, New York City</i></p> <p>Role of Antigen-Processing Machinery in the In Vitro Resistance of Squamous Cell Carcinoma of the Head and Neck Cells to Recognition by CTL <i>Andres Lopez, MD, University of Pittsburgh Cancer Institute, Pittsburgh</i></p> <p>Targeting the Tumor Microenvironment with CpG-ODN Modifies Suppressor Cells Within the Tumor Resulting in Tumor Rejection <i>Joseph Lustgarten, PhD, Mayo Clinic Arizona, Scottsdale</i></p> <p>Tumor-Secreted Factors Induce Normal Endothelial Cells to Inhibit Immune Cell Functions <i>Jennifer Mulligan, Medical University of South Carolina, Charleston</i></p> <p>Tumor-Induced CD4+CD25+ Regulator T-Cells Dampen Effective Anti-Tumor Activity <i>Zhaoyang You, PhD, University of Pittsburgh, Pittsburgh</i></p> <p>Recognition and Elimination of Tumor-Promoting Myeloid Cells by CD8+ CTL Cells Lead to Potent Inhibition of Tumor Growth <i>Bin Zhang, MD, University of Chicago, Chicago</i></p>	
1:40 – 9:30 p.m.	
Poster Session	Palm/Bay
4:00 – 5:00 p.m.	
Poster Authors 1-40 available for questions	Palm/Bay
6:30 – 8:00 p.m.	
Dinner	Gulf/Beach
8:00 – 9:30 p.m.	
Session 5: Cancer Immunotherapy – Successes and Challenges	Island Ballroom
Chairperson: V. Sondak, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa	

<p>Autoimmunity and Vaccination in Melanoma <i>Jeff Weber, MD, PhD, University of Southern California, Los Angeles</i></p> <p>Dendritic Cells as Vectors and Targets in Cancer Immunotherapy <i>Anna Karolina Palucka, MD, PhD, Baylor Institute of Immunology Research, Dallas</i></p> <p>Targeting the CD40 Pathway for Cancer Therapy <i>Robert H. Vonderheide, MD, DPhil, University of Pennsylvania School of Medicine, Philadelphia</i></p>	
Saturday, January 27, 2007	
Registration begins at 7 a.m.	Lobby 3
7:00 – 8:00 a.m.	
Breakfast	Palm/Bay
8:00 – 10:00 a.m.	
Session 6: Immature Myeloid Suppressive Cells & Tumor Escape	Island Ballroom
Chairperson: M. Fishman, MD, PhD, H. Lee Moffitt Cancer Center & Research Institute, Tampa	
<p>T-Cell Tolerance Induced by Immature Myeloid Cells <i>Dmitry Gabrilovich, MD, PhD, H. Lee Moffitt Cancer Center & Research Institute, Tampa</i></p> <p>Inflammatory Monocytes Induced by Tumors Alter T-Lymphocyte Responsiveness through L-Arginine Metabolism <i>Vincenzo Bronte, MD, University of Padua, Padua</i></p> <p>Arginine Availability Regulates the Immune Response in Cancer Patients <i>Augusto Ochoa, MD, Louisiana State University, New Orleans</i></p> <p>Immune Suppression and Inflammation in Tumor Progression <i>Suzanne Ostrand-Rosenberg, PhD, University of Maryland, Baltimore</i></p>	
10:00 – 10:30 a.m.	
Break	Palm/Bay
10:30 – 12:30 p.m.	
Session 7: The Role of Tumor Microenvironment in Tumor Escape	Island Ballroom
Chairperson: E. Sotomayor, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa	
Cross-Targeting to Destroy the Tumor Microenvironment	

<p><i>Hans Schreiber, MD, PhD, University of Chicago, Chicago</i></p> <p>Expression of Indoleamine 2,3-Dioxygenase by Tumor Cells as an Immune Resistance Mechanism That Can Be Fought <i>Benoit Van den Eynde, MD, PhD, Ludwig Institute for Cancer Research, Brussels, Belgium</i></p> <p>Human Tumor Antigens, Tumor Immunosurveillance and Tumor Escape <i>Olivera J. Finn, PhD, University of Pittsburgh, Pittsburgh</i></p> <p>IDO, Cross-Presentation and Tolerance <i>David Munn, MD, Medical College of Georgia, Augusta</i></p>	
12:30 – 1:30 p.m.	
Lunch	Rusty's Dining Room
1:40 – 4:00 p.m.	
Session 8: Cellular and Molecular Mechanisms of Immune Suppression in Cancer	Island Ballroom
Chairperson: E. Celis, MD, PhD, H. Lee Moffitt Cancer Center & Research Institute, Tampa	
<p>Bringing Immune Response to Tumor Sites to Generate CTL for Metastasis <i>Yang-Xin Fu, MD, PhD, University of Chicago, Chicago</i></p> <p>TGF-Beta Inhibition Augments Immunogene Therapy and Adoptive Transfer of Lymphocytes <i>Steven Albelda, MD, University of Pennsylvania, Philadelphia</i></p> <p>Mammary Tumor-Associated Growth Factor Overexpression and Expansion of Immature Myeloid Suppressor Cells <i>Moses Donkor, University of Nebraska Medical Center, Omaha</i></p> <p>Reversing Tumor Immune Suppression with Intra-tumoral IL-12: Activation of Tumor-Associated T-Effector/Memory Cells and Induction of T-Suppressor Apoptosis <i>Nejat Egilmez, PhD, University of Louisville, Louisville</i></p> <p>Combined Chemoimmunotherapy Can Efficiently Break Self-Tolerance and Induce Anti-Tumor Immunity in a Tolerogenic Murine Tumor Model <i>Chang-Yui Kang, PhD, National University of Seoul, Seoul</i></p> <p>Vaccination with Leukemia Cells Expressing Cell Surface-Associated GM-CSF Blocks Leukemia Induction in Immunocompetent Mice <i>Xiaoyang Ling, PhD, M.D. Anderson Cancer Center, Houston</i></p>	

Development of Adenoviral Vectors Interfering with the Jak/STAT Pathway to Overcome Tumor Induced DC Suppression <i>Dinja Oosterhoff, PhD, VU University Medical Center, Amsterdam</i>	
1:40 – 9:30 p.m.	
Poster Session	Palm/Bay
4:00 – 5:00 p.m.	
Poster Authors 41-76 available for questions	Palm/Bay
6:30 – 8:00 p.m.	
Dinner	Gulf Beach
8:00 – 9:00 p.m.	
Session 9: Cancer Immunotherapy – Successes and Challenges	Island Ballroom
Chairperson: A. Sloan, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa	
Adoptive T-Cell Therapy of Renal Cell Cancer <i>Alfred Chang, MD, University of Michigan, Ann Arbor</i>	
Disruption of Regulatory Pathways to Enhance the Efficacy of Cancer Vaccines <i>Johannes Vieweg, MD, FACS, University of Florida College of Medicine, Gainesville</i>	
Sunday, January 28, 2007	
Registration begins at 7 a.m.	Lobby 3
7:00 – 8:00 a.m.	
Breakfast	Lobby 3
8:00 – 10:00 a.m.	
Session 10: Molecular Mechanisms of Negative Signaling in Tumor Escape	Island Ballroom
Chairperson: C. Anasetti, MD & S. Dessureault, MD, PhD, H. Lee Moffitt Cancer Center & Research Institute, Tampa	
Targeting Signaling Pathways in Antigen Presenting Cells to Overcome Tolerance to Tumor Antigens <i>Eduardo Sotomayor, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa</i>	
Antigen Presentation Attenuators and Anti-Tumor Immunity	

<p><i>Si-Yi Chen, MD, PhD, Baylor College of Medicine, Houston</i></p> <p>Cancer Immunoediting: Basic Mechanisms and Therapeutic Implications <i>Robert Schreiber, PhD, Washington University, St. Louis</i></p> <p>Promotion of a Type-1 Cell Response in Metastatic RCC Patients by SU11248; Modulation of a T-Reg Population <i>Jim Finke, PhD, Cleveland Clinic Foundation, Cleveland</i></p>	
10:00 – 10:30 a.m.	
Break	Lobby 3
10:30 – 1:00 p.m.	
Session 11: Regulatory T-Cells & Tumor Escape	Island Ballroom
Chairperson: R. Wiltrot, PhD, National Cancer Institute, Bethesda	
<p>Regulatory T-Cells <i>Alexander Rudensky, PhD, University of Washington, Seattle</i></p> <p>Regulatory T-Cells in Cancer <i>Tyler Curiel, MD, MPH, San Antonio Cancer Center, San Antonio</i></p> <p>Inhibiting T-Reg Activity in Tumor Bearers <i>Mario P. Colombo, PhD, Istituto Nazionale Tumori, Milan</i></p> <p>Role of STAT3 in Mediating a Cross Talk Between Tumor and Regulatory T-Cells <i>Hua Yu, PhD, Beckman Research Institute at City of Hope National Medical Center, Duarte</i></p> <p>Regulatory NKT Cells in Tumor Immunosurveillance and Cancer Vaccines <i>Jay Berzofsky, MD, PhD, Center for Cancer Research, NCI, Bethesda</i></p>	
1:00 – 2:00 p.m.	
Lunch	Rusty's Dining Room
2:00 – 4:00 p.m.	
Session 12: Round Table Discussion: The Mechanism of Tumor Immune Suppression and Potential Approaches to Their Targeting/Closing Remarks	Island Ballroom
Participants will include representatives from biotech and pharmaceutical companies, as well as the FDA and NCI to help expedite clinical trials that will produce meaningful benefits to cancer patients.	